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ABSTRACT: Serine/arginine-protein kinase 1 (SRPK1) regu-
lates alternative splicing of VEGF-A to pro-angiogenic isoforms
and SRPK1 inhibition can restore the balance of pro/
antiangiogenic isoforms to normal physiological levels. The lack
of potency and selectivity of available compounds has limited
development of SRPK1 inhibitors, with the control of alternative
splicing by splicing factor-speciﬁc kinases yet to be translated. We
present here compounds that occupy a binding pocket created by
the unique helical insert of SRPK1, and trigger a backbone ﬂip in
the hinge region, that results in potent (<10 nM) and selective
inhibition of SRPK1 kinase activity. Treatment with these
inhibitors inhibited SRPK1 activity and phosphorylation of serine/arginine splicing factor 1 (SRSF1), resulting in alternative
splicing of VEGF-A from pro-angiogenic to antiangiogenic isoforms. This property resulted in potent inhibition of blood vessel
growth in models of choroidal angiogenesis in vivo. This work identiﬁes tool compounds for splice isoform selective targeting of
pro-angiogenic VEGF, which may lead to new therapeutic strategies for a diversity of diseases where dysfunctional splicing drives
disease development.
Vascular endothelial growth factor A (VEGF-A) is a keyangiogenic factor in new blood vessel formation (angio-
genesis)1 and a critical driver of neovascular eye diseases2
including diabetic retinopathy, exudative (wet) age related
macular degeneration (wAMD), and cancer progression.3 Many
current clinical treatments, such as the monoclonal antibody
Avastin (Bevacizumab) or antibody fragment Lucentis
(ranibizumab), inhibit the action of VEGF-A in vivo.4 These
broad anti-VEGF therapies are expensive, have the potential to
generate signiﬁcant cardiovascular and other oﬀ-target
toxicities, and in eye disease must be administered by regular
intraocular injection. There is, therefore, a need for a novel
approach to VEGF-A inhibition that is cheaper, safer, and easier
to administer.
VEGF-A actually exists as a number of isoforms, generated
by alternative splicing of the eight-exon VEGFA gene, and these
isoforms have diﬀerent biological activities.5 VEGF-A pre-
mRNA can be alternatively spliced through a 3′ alternative
splicing event in the terminal exon, generating isoforms with
distinct and opposing functions.6 Proximal splice site (PSS)
selection produces a pro-angiogenic isoform termed VEGF-
A165a, whereas distal splice site (DSS) selection generates an
antiangiogenic, but cytoprotective, isoform termed VEGF-
A165b.
7 Angiogenesis occurs when the balance between pro- and
antiangiogenic forms of VEGF-A is switched by diﬀerential
splicing of the VEGF-A mRNA to the pro-angiogenic form.
VEGF-A165b is endogenously expressed in normal tissues and
downregulated in diabetic retinopathy and has been shown to
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inhibit VEGF-A165a-mediated angiogenesis in physiological,
pathological, and experimental settings.8
Serine/arginine (SR) proteins such as serine arginine-rich
splicing factor 1 (SRSF1) regulate VEGF-A splicing by binding
to the mRNA in a phosphorylation-dependent manner.9−11
Speciﬁc splice factor kinases are responsible for the
phosphorylation of the SRSF proteins and can be used to
modulate the splicing events10,11 For example, serine/arginine-
protein kinase 1 (SRPK1) regulates splicing of pro-angiogenic
VEGF-A165a through phosphorylation of SRSF1, enabling
SRSF1 nuclear translocation and binding to the proximal
splice site in VEGF-A pre-mRNA.12
Modulation of this kinase can restore the balance of isoforms
to normal, without harming cell function,10,11 particularly of the
eye,13 as well as in cancer.14,15 Knockdown or inhibition of
SRPK1 in models of neovascular eye disease,16 colorectal
cancer,17 prostate cancer,18 or melanoma19 leads to distal splice
site selection, generation of antiangiogenic VEGF-A165b, and
reduced disease progression.
SRPK1 inhibitors have been proposed as potential
therapeutics in angiogenic-related diseases, viral replication,
and potential anticancer agents. However, existing classes of
S R P K 1 i n h i b i t o r s , t h e ( t r i ﬂ u o r o m e t h y l ) -
phenylisonicotinamides,20 tricyclic quinoxaline derivatives,21
and 2-triﬂuoro-methyl-5,6-dihydro-7H-[1,3,4]thiadiazolo[3,2-
a]pyrimidin-7-ones,22 are neither speciﬁc nor potent. The
discovery of quality leads with suitable pharmacological proﬁles
for optimization and use as topical applications would be a
signiﬁcant advance.
Development of highly selective kinase inhibitors is
challenging due to the high similarity of the ATP binding site
that is usually targeted.23 Here, we describe experiments where
we have taken advantage of combining a unique property of a
speciﬁc insert close to the kinase hinge region in the SRPK
family24 with the presence of an unusual glycine residue that
can allow a backbone ﬂip, to rationally develop highly speciﬁc,
very potent inhibitors of SRPK1 that are eﬀective as eye drops
in preventing neovascular eye disease in animal models.
■ RESULTS AND DISCUSSION
We recently identiﬁed a 3-(triﬂuoromethyl)anilide scaﬀold
(SPHINX) with moderate potency but high selectivity for
SRPK1 (Figure 1a,c).16 This inhibitor demonstrated that
inhibition of SRPK allows for modulation of the VEGF-A
splicing switch in vivo and in vitro. SPHINX was discovered
through a screening campaign using diﬀerential scanning
ﬂuorimetry (DSF)25 and in an in vitro kinase assay has an
IC50 of 880 nM for SRPK1. We investigated whether more
potent molecules could be identiﬁed while maintaining target
selectivity. Screening of a small series of related molecules
identiﬁed compound 1, where the morpholine substituent was
replaced with a piperazine moiety, which showed an IC50 of 31
nM (Figure 1a,c). A subsequent DSF screen against 55 kinases,
which were selected based on cross reactivity of inhibitors
targeting splicing kinases, showed that 1 interacted selectively
with SRPK1 (ΔTm 8.54 °C) and SRPK3 (ΔTm 8.49 °C) over
all of the other kinases tested, including SRPK2 (ΔTm < 4 °C,
Supporting Information Table 1).
To guide our inhibitor design, we solved a high resolution
crystal structure of SRPK1 in complex with 1 (Figure 2). The
structure of the complex provided a rationale for the selectivity
of this inhibitor for the SRPK family. Structures of SRPKs
revealed that a helix in the SRPK insertion domain packs
adjacent to the kinase hinge region, creating a unique
hydrophobic pocket. The CF3 group of 1 was oriented toward
this hydrophobic pocket, tightly interacting with this SRPK
family speciﬁc binding cavity (Figure 2c).
The structure of SRPK1 in complex with 1 provided a model
for a rational design of improved SRPK1 inhibitors. From
examination of the binding site, we hypothesized that variation
of Y and Z in the SPHINX scaﬀold (Figure 1b) with groups
that could act as hydrogen-bond acceptors to interact with the
catalytic lysine (K109) and/or the altered DFG (DLG)
sequence in SRPK1 would improve potency, while maintaining
interaction with the α-helix of the SRPK insertion domain.
To this end, a small library of compounds was prepared from
which we conﬁrmed that replacement of the methyl substituent
on the furan ring of 1 with a 4-pyridine group improved
potency (i.e. compound 2, which is 20 nM), while further
Figure 1. SPHINX compounds, inhibitors of SRPK1. (A) Structures of
SPHINX and 1. (B) The SPHINX scaﬀold and structures of 2, 3, and
SPHINX31. (C) IC50 of compounds. (D) Radioactive SRPK1 kinase
assay dose response with SPHINX31. (E) Isothermal calorimetry of
SPHINX31 binding to SRPK1.
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improvement in potency was found by extending the
substituent on the piperazine (Figure 1c). SPHINX31 emerged
as a compound of excellent potency, with an IC50 of 5.9 nM
(Figure 1d), and we therefore chose this inhibitor as a chemical
probe for further evaluation. Direct binding assays by
isothermal titration calorimetry conﬁrmed tight binding to
SRPK1. The measured binding isotherm resulted in the
determination of a dissociation constant of 72 ± 5 nM and a
favorable binding enthalpy (ΔH: −5.98 ± 0.2 kcal/mol) and
entropy (TΔS: 3.9 kcal/mol; Figure 1e).
The crystal structure of SPHINX31 with SRPK1 revealed
structural features leading to the high potency and selectivity of
this inhibitor (Figure 3). The binding mode of SPHINX31 was
well-deﬁned by electron density, and the structure was reﬁned
at 1.7 Å resolution (Supporting Information Table 2). As
observed in the structure of SRPK1 with 1, the CF3 group
interacted with the unique domain insert by binding to a deep
hydrophobic cavity formed by the inset side chains of Y227,
I228, and L231 and the hinge residue V167 (Figure 3b). The
kinase catalytic domain assumed an active conformation as
indicated by the presence of the canonical active site salt bridge
(K109; E124) alignment of the hydrophobic spines and the “in”
position of the altered DFG (DLG in SRPK1) motif. The 4-
pyridine group attached to the furan projects into the binding
site, interacting with E124. In addition, the 4-pyridine moiety
stacks against the aromatic sides chain of the gatekeeper
(F165). The pyridine attached to the piperazine ring orients
toward the P-loop, accommodating a hydrophobic pocket
formed by V94, S92, and P-loop main chain atoms. The
improved contacts, in particular the aromatic stacking
interactions, provide a rationale for the signiﬁcantly improved
inhibitor potency of SPHINX31 when compared with 1.
When compared with the SRPK1 apo-structure, the
SPHINX31 complex revealed several inhibitor-induced
changes. Most signiﬁcantly, the backbone carbonyl of the
hinge residue L168 ﬂipped to make room for the triﬂuor-
omethyl group (Figure 3b). The phosphate binding loop (P-
loop) also signiﬁcantly changed conformation when compared
with the structure of the apo-kinase domain. This loop region
across kinases is usually very dynamic, but in SRPK1 it is
unusually rich in aromatic residues, which normally results in
decreased movement. However, here, the P-loop is distorted to
allow tighter contact of side chain residues with the inhibitor.
In the kinase hinge region, structural change induced by
ﬂipping of the backbone carbonyl of the hinge residue is
facilitated by the presence of the glycine residue (G169) that
introduces ﬂexibility in this region. Glycine residues are rare in
hinge regions, but similar backbone ﬂips have been evoked as
the structural mechanism explaining the excellent selectivity of
the p38 inhibitor skepionone L.26 A similar backbone ﬂip has
also been observed in the recent report27 of SRPIN340,
supporting our hypothesis that this structural change oﬀers an
interesting opportunity for the design of inhibitor selectivity.
Figure 2. X-ray crystallography of 1 in SRPK1. (A) Co-crystallography
of 1 in SRPK1 (pdb id = 5MXX). (B) Structure of tool compound 1
(left panel) and 2FoFc electron density map around the ligand (right
panel). (C) Ribbon structure showing P loop (green), 1, and
highlighting the CF3 group interacting in the hydrophobic pocket
located in the SRPK speciﬁc insert region.
Figure 3. X-ray crystallography of SPHINX31 in SRPK1. (A) Co-
crystal structure of SPHINX31 bound to SRPK1 (pdb id = 5MY8).
(B) Overlay of hinge region of unbound (orange) and SPHINX31-
bound (gray) SRPK1. It can be seen that the triﬂuoromethyl group
(cyan) interacts with the glycine to ﬂip the hinge outward (arrow).
The ATP binding pocket of SPHINX31 unbound (orange) and
SPHINX31-bound (gray) SRPK1 shows that the phosphorylation (P)-
loop is substantially pushed upward by SPHINX31.
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The SPHINX scaﬀold has high selectivity19 for SRPK1 over
SRPK2, and this selectivity can be rationalized by the
diﬀerences in the helical insert region, with the key residues
in this region for SRPK1 being Y227, I228, and L231, while in
SRPK2, I228 is replaced by a valine (V240) and L231 is
replaced by a methionine (M243). We were able to solve a
crystal structure of SRPK2 in complex with 1, and as can be
seen in the overlay of the two crystal structures
SPHINX31.SRPK1 and 1.SRPK2 (Supporting Information
Figure 1), the methionine residue is signiﬁcantly larger than
the leucine residue in SRPK1, which makes the pocket in
SRPK2 smaller and results in a slight reorientation of the
inhibitor and the CF3 group. As a consequence, 1 cannot bind
as tightly to SRPK2 as indicated by the lengthening of the H-
bond between V167 and the amido group (1.82 Å versus 1.72
Figure 4. SPHINX31, highly selective for SRPK1. (A) Diﬀerential scanning ﬂuorimetry temperature shift of SPHINX31 against SRPK1 and closely
related kinases. (B) International Centre for Kinase Proﬁling screen of SPHINX31 against a series of key 50 enzymes that provide representative
sampling of the human kinome.
Figure 5. Inhibition of cellular SRPK1 activity. (A) Dose response of
SPHINX31 inhibits TNFα-mediated SRSF1 phosphorylation. Immu-
noprecipitation with SRSF1 antibody and immunoblotting with
phosphoSR in PC-3 cells to detect phosphorylated SRSF1 (n = 3
independent experiments). (B) Quantitation of the westen blot bands
shown in panel A. The ratio between phosphor and unmodiﬁed SRSF1
is shown. Quantiﬁcation of pSR/SRSF1 ratio indicates an IC50 of 367.3
nM for SPHINX31. (C) Dose response with SPHINX31 and
immunoblotting for VEGF165b in RPE cells. Tubulin is used to
control for equal loading. n = 3 dose response inhibitor treatments.
Figure 6. Ocular penetration of SPHINX31. (A) Amount (ng per mg
of tissue) of SPHINX31 following single 0.05 μg/10 μL eye drop
administration in the indicated eye tissue and (B) in plasma and
systemic organs. Dashed line is IC50 on plasma axis. The inset shows a
blowup of the bottom left-hand corner of the graph showing
detectable SPHINX31 in plasma at low concentration.
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Å) and the distance between Y227 and the CF3 group (3.7 Å in
SRPK2; 3.3 Å in SRPK1).
Due to their role in splicing, we were particularly interested
in the activity of the developed inhibitors on all of the splicing
modulating kinases. We therefore used diﬀerential scanning
ﬂuorimetry to screen SPHINX31 against this subgroup of
kinases; CLK family (CLK1, -2, -3, -4), DYRK1A and DYRK2
as well as PRBF4B (DYRK5), the SRPK family (SRPK1, -2, and
-3), and the PIM1 and PIM2 kinases, which we have found
often interact with splicing kinase inhibitors. As expected, the
ΔTm data showed strong interaction for SRPK1 (ΔTm of 12.8
°C); weak binding to SRPK2, CLK1 (ΔTm of 6.7 °C), and
CLK4 (ΔTm of 5.7 °C); and no signiﬁcant ΔTm shifts for other
splicing kinases (Figure 4a). This degree of diﬀerence in
temperature shift (6.1 °C for SRPK2 and CLK1 compared with
SRPK1, and 7.1 °C for CLK4) equates to a diﬀerence in
binding aﬃnity of 50-fold for SRPK2 and CLK1 and 100-fold
for CLK4,25 conﬁrming the high selectivity of SPHINX31 for
SRPK1.
Kinase assays showed that SPHINX31 was a type 1 kinase
inhibitor (ATP competitive, Supporting Information Figure 2).
A radiolabeled ATP competition assay was carried out against
50 kinases, which have been selected by the International
Centre for Kinase Proﬁling as being representative of the
human kinome, including SRPK1. This demonstrated 96%
inhibition of SRPK1 activity at 1 μM by SPHINX31, but no
other kinase was signiﬁcantly inhibited in that panel (Figure
4b).
To determine whether SPHINX31 inhibits SRPK1 activity in
cells, PC3 prostate cancer cells (previously been shown to have
high SRPK1 mediated SRSF1 phosphorylation18) were treated
with SPHINX31. This resulted in inhibition of SRSF1
phosphorylation at an inhibitor concentration of 300 nM
(Figure 5a,b). Quantitative analysis of the Western blot bands
Figure 7. Metabolic stability of SPHINX31. (A) % SPHINX31
remaining at the indicated time points in mouse plasma after
incubation at 37 °C. (B) % SPHINX31 remaining at the indicated
time points after incubation with mouse liver microsomes.
Figure 8. Antiangiogenic eﬃcacy of SRPK1 inhibitor eye drops. (A)
Fluorescein angiography representative images at day 7 and day 14
after laser CNV induction in C57/Bl6 mice with vehicle, SPHINX31
(2 μg/mL or 20 μg/mL) and pazopanib (20 μg/mL and 250 μg/mL).
(B) Quantiﬁcation of area × intensity for SPHINX31. N (lesion) =
152 (DMSO), 36 (SPHINX31, 0.2 μg/mL), 36 (SPHINX31, 2 μg/
mL), 46 (SPHINX31, 20 μg/mL). (C) RPE/choroid ﬂatmount Imaris
representative images for DAPI, isolectin B4, and CD45 immuno-
ﬂuorescence after 14 days treatment with DMSO, pazopanib (20 μg/
mL), or SPHINX31 (2 μg/mL). (D) Quantiﬁcation of isolectin B4
area × intensity (% DMSO controls). (E) Number of immune cells (%
DMSO controls). **p < 0.01, Kruskall−Wallis ANOVA (N (lesion) =
30 (DMSO), 12 (SPHINX31, 2 μg/mL), 16 (Pazopanib, 20 μg/mL)).
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revealed an EC50 of about 360 nM (Figure 5b). The eﬀect on
downstream splicing activity was also investigated in retinal
pigmented epithelials (RPE, a major source of VEGF in the
retina). The compounds dose-dependently switched splicing
from VEGF-A165a to VEGF-A165b in RPE cells (Figure 5c).
The VEGF-A165b antibody detects the C-terminal sequence
of VEGF encoded by exon 8b. A recent report28 showed that it
is possible to generate a form of VEGF by post-translation
readthrough (PTR), where the stop codon in exon8a is
repressed, resulting in an extended VEGF (VEGF-Ax), which is
antiangiogenic and can be detected by the VEGF-A165b
antibodies. To determine whether SPHINX31 was causing
splicing to VEGF-A165b and not production of VEGF-Ax by
PTR, an immunoblot of RPE cells was undertaken with a
VEGFAx speciﬁc antibody. VEGF-Ax was not found in
untreated RPE cells (Supporting Information Figure 3).
We had previously shown that SRPK1 inhibition by
SRPIN340 (IC50 0.96 μM) or SPHINX (IC50 0.88 μM) was
antiangiogenic in mouse models of choroidal neovascularisa-
tion, as eye drops with a maximum eﬀect at 10 μg/mL (28.5
μM).16 To determine whether more potent molecules retain
ocular penetration, we measured the amount of SPHINX31
retained in ocular compartments after application to the surface
of the eye in eye drops. A total of 0.05 μg of SPHINX31 was
applied to the left eyes of 12 mice; then the animals were
sacriﬁced and samples collected at 1, 4, 8, and 24 h (N = 1 per
time point). Retinae were dissected from the scleral/choroidal
complex and SPHINX31 measured. Figure 6A shows that
SPHINX31 was found in retinae and sclera/choroid at similar
levels, equivalent to approximately 0.24% (retina) and 0.43%
(sclera/choroid) of the starting dose in these tissues at 4 h after
application of the eye drop. Figure 6B shows that there was an
initial low spike in SPHINX31 in plasma at 1 h (2 nM), which
was lost by 2 h and detectable at only very low levels at all other
time points. In the kidney and heart, trace amounts (<0.01 ng/
mg tissue) of SPHINX31 could be detected only after 24 h.
To determine stability, we measured levels of SPHINX31 in
mouse plasma after incubation at 37 °C. Figure 7A shows that
SPHINX31 is rapidly broken down. Metabolic stability in
mouse liver microsomes showed that SPHINX31 had medium
clearance with a T1/2 of 95.79 min compared to the positive
control Verapamil T1/2 of 11.15 min (Figure 7B). Rapid
clearance can improve the therapeutic window through reduced
risk of oﬀ-target eﬀects, and this is an important consideration
in ongoing research for both eye drop administration and
development of systemic therapeutics.
Cell-based assays of cytotoxicity (Supporting Information
Figure 4) were carried out for the compounds that were potent
inhibitors. Compound 3 had an EC50 of 10−50 μM, whereas
the EC50 for 1 and SPHINX31 was larger than 100 μM, and 1
and SPHINX31 showed <5% toxicity at 100 μM. Ames tests
indicated that neither SPHINX31 nor its breakdown product
showed any genotoxicity. Addition of SPHINX31 as an eye
drop to mice demonstrated no alteration in electro-retinogram
signals (Supporting Information Figure 5). We also tested
whether SPHINX31 could inhibit the human ether a-go-go
related gene (hERG) potassium channel using patch clamp
electrophysiology. While SPHINX did not inhibit hERG, as we
had previously described,16 we found that compound 3 did,
with an IC50 of 36 nM. In contrast, SPHINX31 inhibited hERG
with an IC50 of 300 nM (Supporting Information Figure 6).
This is 50-fold higher than its IC50 value against SRPK1 (5.9
nM), so, combined with relatively rapid clearance, it is believed
that hERG inhibition is not a signiﬁcant issue for this
compound.
Having established that SPHINX31 could penetrate into the
eye and that it was not toxic, we therefore tested the eﬀect of
SPHINX31 as an eyedrop in a mouse model of choroidal
neovascularization, which models wet age-related macular
degeneration (Figure 8A).22,23 SPHINX31 exerted a dose
dependent inhibition of choroidal neovascularisation (Figure
8B), with similar eﬃcacy at 2 μg/mL (3.8 μM) to that achieved
by SPHINX or SRPIN340 at 10 μg/mL (28.5 μM), and greater
eﬀect at 2 μg/mL than pazopanib at 250 μg/mL (572 μM).
Staining of choroid for endothelial cells (isolectin-B4) and
inﬁltrating macrophages (CD45) demonstrated that both
pazopanib and SPHINX31 inhibited blood vessel growth and
macrophage inﬁltration (Figure 8C,D). The level of inhibition
of lesion size (∼50%) is similar to that seen with inhibitors of
VEGF (e.g., VEGF-TRAP, 30%),28 recombinant VEGF-A165b
protein (43%),29 or intraocular injection of SRPK1 inhib-
itors6,19,21 Extraction of protein from the retinae of the animals
demonstrated VEGF-A165b expression in the retinae, which was
greater in treated than in nontreated eyes measured both by
Western blot (Supporting Information Figures 7A,B) and by
isoform speciﬁc ELISA, where a switch in splicing was seen
toward antiangiogenic VEGF (Supporting Information Figure
7C−E). Coupled with our earlier observation of the
penetration of SPHINX31 into the retina, we believe that
these data show that SPHINX31 represents a good lead for the
development of antiangiogenic therapeutics in the eye.
In summary, we have shown here the development of highly
potent, selective, and cell active SRPK1 inhibitors. Importantly,
these compounds also have antiangiogenic properties in vivo.
These compounds occupy a binding pocket created by the
unique helical insert of SRPK1 and trigger a backbone ﬂip in
the hinge region that results in potent (<10 nM) and selective
inhibition of SRPK1 kinase activity. SPHINX31 emerged as the
most optimal inhibitor of a series of inhibitors that were
synthesized. SPHINX31 showed good cellular activity,
promising pharmacokinetic properties and potency in in vivo
models of angiogenesis. SPHINX31 will facilitate the develop-
ment of topical therapeutics for neovascular eye disease and
provide validation of SRPK1 as a target for drug development
in multiple diseases.
■ METHODS
All of the methods and procedures are presented in the Supporting
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Obert, S., Klebl, B., Keŕi, G., and Őrfi, L. (2005) Synthesis of selective
SRPK-1 inhibitors: novel tricyclic quinoxaline derivatives. Bioorg. Med.
Chem. Lett. 15, 3241−3246.
ACS Chemical Biology Articles
DOI: 10.1021/acschembio.6b01048
ACS Chem. Biol. 2017, 12, 825−832
831
(22) Morooka, S., Hoshina, M., Kii, I., Okabe, T., Kojima, H., Inoue,
N., Okuno, Y., Denawa, M., Yoshida, S., Fukuhara, J., Ninomiya, K.,
Ikura, T., Furuya, T., Nagano, T., Noda, K., Ishida, S., Hosoya, T., Ito,
N., Yoshimura, N., and Hagiwara, M. (2015) Identification of a Dual
Inhibitor of SRPK1 and CK2 That Attenuates Pathological Angio-
genesis of Macular Degeneration in Mice. Mol. Pharmacol. 88, 316−
325.
(23) Muller, S., Chaikuad, A., Gray, N. S., and Knapp, S. (2015) The
ins and outs of selective kinase inhibitor development. Nat. Chem. Biol.
11, 818−821.
(24) Ghosh, G., and Adams, J. A. (2011) Phosphorylation
mechanism and structure of serine-arginine protein kinases. FEBS J.
278, 587−597.
(25) Federov, O., Niesen, F. H., and Knapp, S. in Kinase Inhibitors:
Methods and Protocols, Methods Mol. Biol., Vol. 795 (Kuster, B., Ed.) ,
pp 109−118, Springer, 2011.
(26) Koeberle, S. C., Fischer, S., Schollmeyer, D., Schattel, V.,
Grütter, C., Rauh, D., and Laufer, S. A. (2012) Design, Synthesis, and
Biological Evaluation of Novel Disubstituted Dibenzosuberones as
Highly Potent and Selective Inhibitors of p38 Mitogen Activated
Protein Kinase. J. Med. Chem. 55, 5868−5877.
(27) Siqueira, R. P., de Almeida Alves Barbosa, É., Polet̂o, M. D.,
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M. R., Juńior, A. S., Fietto, J. L. R., Kobarg, J., de Oliveira, E. B.,
Teixeira, R. R., Borges, J. C., Yunes, J. A., and Bressan, G. C. (2015)
Potential Antileukemia Effect and Structural Analyses of SRPK
Inhibition by N-(2-(Piperidin-1-yl)-5-(Trifluoromethyl)Phenyl)-
Isonicotinamide (SRPIN340). PLoS One 10, e0134882.
(28) Saishin, Y., Saishin, Y., Takahashi, K., Lima e Silva, R., Hylton,
D., Rudge, J. S., Wiegand, S. J., and Campochiaro, P. A. (2003) VEGF-
TRAP(R1R2) suppresses choroidal neovascularization and VEGF-
induced breakdown of the blood-retinal barrier. J. Cell. Physiol. 195 (2),
241−8.
(29) Hua, J., Spee, C., Kase, S., Rennel, E. S., Magnussen, A. L., Qiu,
Y., Varey, A., Dhayade, S., Churchill, A. J., Harper, S. J., Bates, D. O.,
and Hinton, D. R. (2010) Recombinant human VEGF165b inhibits
experimental choroidal neovascularization. Invest. Ophthalmol. Visual
Sci. 51 (8), 4282−8.
■ NOTE ADDED AFTER ASAP PUBLICATION
This paper was published on February 6, 2017. The names of
two of the authors (Roya Babaei-Jadidi and Jules C. Hancox)
were incorrectly spelled. This has been corrected and the paper
was re-posted on February 27, 2017.
ACS Chemical Biology Articles
DOI: 10.1021/acschembio.6b01048
ACS Chem. Biol. 2017, 12, 825−832
832
